Updates

Clinigen - On lookout for 3-5 more deals

November 2013

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

Full year results came in over the recently upgraded expectations. Sales were up 49% to Â£122.6m (FY12: Â£82.1m) with all three operating businesses contributing strong organic growth. Pretax profit increased by 29% to Â£20.4m for eps of 20.7p.When we did our main write up on the shares exactly a year ago, we said the potential at Clingen was â€œthe soon-to-be-unveiled purchase of a new drug, which could have the same implications as a big strike for a small oil company and would immediately catapult the company into a bigger league.â€ And so it has been proved with the purchase of oncology toxicity treatment, Cardioxane from Novartis and the in-license of an antibiotic for MRSA, Vibativ, but with the company saying it ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

Regenersis - Acquires Indian laptop repairer

Quindell Portfolio

Clinigen (November 2016)

Clinigen (October 2016)

Clinigen (October 2015)

Clinigen (August 2015)

Clinigen - Completes £225m Idis acquisition (June 2015)

Clinigen (April 2015)

Clinigen (February 2015)

Clinigen - Acquires speciality products (September 2014)

Clinigen - Company reassures investors with trading update (August 2014)

Clinigen (March 2014)

Clinigen - Growing rapidly into valuation (February 2014)

Clinigen - Another upgrade to forecast (September 2013)

Clinigen - First of half a dozen deals (April 2013)

Clinigen - Acquisition anticipated in March (March 2013)

Clinigen - Trial services to grow at 17% annual clip (December 2012)

Clinigen - New issue growing like topsy (November 2012)

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X